IP Library Patent Application 10588419
Patent Application
App. No. 10/588,419

Photodynamic Therapy For The Treatment Of Hyperactive Sebaceous Gland Disorders Using Topically Applied Hydrophobic Green Porphyrins

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/588,419
Abstract

The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.

Claims (22)

1 . A method to treat hyperactive sebaceous gland disorders which method comprises:

(i) topically applying a hydrophobic and/or lipophilic photosensitizer composition to skin tissue exhibiting symptoms of acne, and

(ii) exposing the tissue to energy at a wavelength capable of activating the photo sensitizer.

2 . The method of claim 1 wherein the disorder is selected from acne, seborrhea, seborrheic dermatitis, and sebaceous gland hyperplasia.

3 . The method of claim 1 , wherein the photosensitizer is selected from lipophilic photosensitizers.

4 . The method of claim 1 , wherein the photosensitizer is selected from hydrophobic photosensitizers.

5 . The method of claim 1 , wherein the photosensitizer is selected from the group consisting of 5-aminolevulinic acid and derivatives thereof, 5-aminolevulinic acid esters and derivatives thereof, porphyrins and derivatives thereof, methylene blue and derivatives thereof, bacteriochlorophyll and derivatives thereof, and combinations thereof.

6 . The method of claim 1 , wherein the photosensitizer is selected from the group consisting of 5-aminolevulinic acid, 5-aminolevulinic acid esters, chlorins, bacteriochlorins, isobacteriochlorins, phthalocyanine, naphthalocyanines, pyropheophorbides, sapphyrins, texaphyrins, tetrahydrochlorins, purpurins, porphycenes, phenothiaziniums, bacteriochlorophyll, bacteriochlorophyll derivatives, pro-porphyrins, porphyrins, and combinations thereof.

7 . The method of claim 1 , wherein the photosensitizer is selected from the group consisting of verteporfin, lemuteporfin, and combinations thereof.

8 . The method of claim 1 , wherein the composition has a viscosity at 20° C. of from about 50 cps to about 50,000 cps.

9 . The method of claim 1 , wherein excess photosensitizer composition is removed from the skin prior to application of said energy.

10 . The method of claim 1 , wherein the hyperactive sebaceous gland disorder is acne and the treatment is repeated until the total number of acne lesions has been reduced by 30% or greater.

11 . The method of claim 1 , wherein steps i) and ii) are repeated at least once every six months.

12 . The method of claim 1 , wherein steps i) and ii) are repeated at least once every three months.

13 . The method of claim 1 , wherein steps (i) and (ii) are repeated at intervals of not less than 5 days.

14 . The method of claim 1 , wherein the hyperactive sebaceous gland disorder is acne and the treatment method further includes at least one non-photodynamic treatment for acne.

15 . The method of claim 14 , wherein the non-photodynamic treatment at least one topical treatment.

16 . The method of claim 14 , wherein the non-photodynamic treatment is administering one or more agents selected from the group consisting of topical retinoids, oral retinoids, systemic antibiotics, topical or local antibiotics, oral contraceptives, topical anti-androgens, anti-progestins, blue light therapy, laser therapy, and combinations thereof.

17 . The method of claim 14 wherein the non-photodynamic treatment comprises administering one or more topical retinoids.

18 . The method of claim 1 , wherein said energy is at least in part supplied by a light emitting diode device.

19 . The method of claim 18 wherein the device emits red and blue light.

20 - 21 . (canceled)

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 28, 2026
From: SOUTHFIELD MEZZANINE CAPITAL II LP
To: SOMNUS ACQUISITION, LLC
Reel/Frame 073614/0160 →
ADDRESS CHANGE Recorded May 15, 2014
From: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 032897/0450 →
PATENT ASSIGNMENT AGREEMENT Recorded Dec 9, 2013
From: QLT INC.; QLT OPHTHALMICS, INC.
To: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Reel/Frame 031784/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2007
From: CURAUDEAU, ALAIN H.; NEYNDORFF, HERMA C.; TAO, JING-SONG; LEVY, JULIA G.; HUNT, DAVID W.C.; LAM, MORGAN CHUN; RUBINCHIK, VALERY
To: QLT, INC.
Reel/Frame 019987/0655 →